Aktis Oncology: Padcev Is Building The Market Aktis Wants (NASDAQ:AKTS)
· seekingalpha.com
Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. Read more on AKTS stock here.
Most investors likely view Aktis Oncology, Inc. ( AKTS ) as a one-shot stock, which is dependent upon the first quarter 2027 results from the Phase 1b study of ...